Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Multiple Sclerosis

  Free Subscription


Articles published in J Neurol Sci

Retrieve available abstracts of 173 articles:
HTML format



Single Articles


    February 2021
  1. EILAM-STOCK T, Shaw MT, Krupp LB, Charvet LE, et al
    Early neuropsychological markers of cognitive involvement in multiple sclerosis.
    J Neurol Sci. 2021;423:117349.
    PubMed     Abstract available


    January 2021
  2. BOSE G, Freedman MS
    Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis.
    J Neurol Sci. 2021;421:117324.
    PubMed     Abstract available


  3. KOVVURU S, Nalleballe K, Onteddu SR, Sharma R, et al
    Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic.
    J Neurol Sci. 2021;420:117230.
    PubMed     Abstract available


    December 2020
  4. WEBER J, Bernsdorff N, Robinson T, Endres D, et al
    Diagnosis of multiple sclerosis in times of MOG and AQP4 autoantibody testing - A monocentric study.
    J Neurol Sci. 2020;421:117289.
    PubMed     Abstract available


    October 2020
  5. VARMA-DOYLE AV, Lukiw WJ, Zhao Y, Lovera J, et al
    A hypothesis-generating scoping review of miRs identified in both multiple sclerosis and dementia, their protein targets, and miR signaling pathways.
    J Neurol Sci. 2020 Oct 23:117202. doi: 10.1016/j.jns.2020.117202.
    PubMed     Abstract available


  6. BARREIRO-GONZALEZ A, Sanz MT, Carratala-Bosca S, Perez-Miralles F, et al
    Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks.
    J Neurol Sci. 2020;419:117180.
    PubMed     Abstract available


    September 2020
  7. ILARDI M, Nolan-Kenney R, Fatterpekar G, Hasanaj L, et al
    Role for OCT in detecting hemi-macular ganglion cell layer thinning in patients with multiple sclerosis and related demyelinating diseases.
    J Neurol Sci. 2020;419:117159.
    PubMed     Abstract available


  8. CHAUDHRY F, Bulka H, Rathnam AS, Said OM, et al
    COVID-19 in multiple sclerosis patients and risk factors for severe infection.
    J Neurol Sci. 2020;418:117147.
    PubMed     Abstract available


  9. JAKIMOVSKI D, Zivadinov R, Dwyer MG, Bergsland N, et al
    High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis.
    J Neurol Sci. 2020;418:117120.
    PubMed     Abstract available


    August 2020
  10. GELIBTER S, Orrico M, Moiola L, Dagna L, et al
    Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis.
    J Neurol Sci. 2020;418:117104.
    PubMed    


  11. SHAH Z, Wasay M, Chaudhry BZ, Fredrikson S, et al
    Multiple sclerosis in Pakistan: Current status and future perspective.
    J Neurol Sci. 2020;418:117066.
    PubMed     Abstract available


    July 2020
  12. MINACAPELLI E, Giordano A, Falautano M, Sangalli F, et al
    Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios.
    J Neurol Sci. 2020;417:117064.
    PubMed     Abstract available


  13. HUGHES AJ, Patel K, Fitzgerald KC, Brown A, et al
    Reliability and validity of the multiple sclerosis resiliency scale (MSRS).
    J Neurol Sci. 2020;418:116983.
    PubMed     Abstract available


  14. LUCA B, Tommaso G, Bavaro DF, Laura M, et al
    Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
    J Neurol Sci. 2020;416:117011.
    PubMed    


    June 2020
  15. ABBOUD H, Serra A
    The pressing questions in multiple sclerosis Care in the era of COVID-19.
    J Neurol Sci. 2020;416:117005.
    PubMed    


  16. PROCKL V, Nickel FT, Utz KS, Frohlich K, et al
    Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients.
    J Neurol Sci. 2020;415:116973.
    PubMed     Abstract available


  17. WELLER D, Lorincz L, Sutter T, Reuter K, et al
    Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis.
    J Neurol Sci. 2020;416:116978.
    PubMed     Abstract available


    May 2020
  18. LAMARGUE D, Koubiyr I, Deloire M, Saubusse A, et al
    Effect of cognitive rehabilitation on neuropsychological and semiecological testing and on daily cognitive functioning in multiple sclerosis: The REACTIV randomized controlled study.
    J Neurol Sci. 2020;415:116929.
    PubMed     Abstract available


  19. KIM H, Lim YM, Kim G, Lee EJ, et al
    Choroid plexus changes on magnetic resonance imaging in multiple sclerosis and neuromyelitis optica spectrum disorder.
    J Neurol Sci. 2020;415:116904.
    PubMed     Abstract available


  20. AHMED SI, Lohana N, Javed G, Bareeqa SB, et al
    Semantic fluency and cognitive function impairment in multiple sclerosis patients.
    J Neurol Sci. 2020;415:116898.
    PubMed    


    April 2020
  21. FALSAFI Z, Tafakhori A, Agah E, Mojarrad M, et al
    Safety and efficacy of memantine for multiple sclerosis-related fatigue: A pilot randomized, double-blind placebo-controlled trial.
    J Neurol Sci. 2020;414:116844.
    PubMed     Abstract available


  22. TSANTES E, Curti E, Collura F, Bazzurri V, et al
    Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2020;414:116827.
    PubMed     Abstract available


    March 2020
  23. CUELLO JP, Martinez Gines ML, Tejeda-Velarde A, Medina Heras S, et al
    Cytokine profile during pregnancy predicts relapses during pregnancy and postpartum in multiple sclerosis.
    J Neurol Sci. 2020;414:116811.
    PubMed     Abstract available


  24. RUSSO C, Cocozza S, Riccio E, Pontillo G, et al
    Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study.
    J Neurol Sci. 2020;412:116782.
    PubMed     Abstract available


  25. SCOTT TF, Bertha N
    The impact of multiple sclerosis relapses on worsening over the long term; insights in the treatment era.
    J Neurol Sci. 2020;413:116773.
    PubMed     Abstract available


  26. FUKUMOTO S, Nakamura Y, Watanabe M, Isobe N, et al
    Risk HLA-DRB1 alleles differentially influence brain and lesion volumes in Japanese patients with multiple sclerosis.
    J Neurol Sci. 2020;413:116768.
    PubMed     Abstract available


    February 2020
  27. OUALLET JC, Radat F, Creange A, Abdellaoui M, et al
    Evaluation of emotional disorders before and during treatment with interferon beta in patients with multiple sclerosis.
    J Neurol Sci. 2020;413:116739.
    PubMed     Abstract available


  28. SOLARO C, Cattaneo D, Basteris A, Carpinella I, et al
    Haptic vs sensorimotor training in the treatment of upper limb dysfunction in multiple sclerosis: A multi-center, randomised controlled trial.
    J Neurol Sci. 2020;412:116743.
    PubMed     Abstract available


  29. RINI AM, Clerici VT, Rinaldi E, Modesto M, et al
    Severe thrombocytopenia during Natalizumab therapy: A case report.
    J Neurol Sci. 2020;409:116587.
    PubMed    


    January 2020
  30. MARTINEZ-LAPISCINA EH, Mahatanan R, Lee CH, Charoenpong P, et al
    Associations of serum 25(OH) vitamin D levels with clinical and radiological outcomes in multiple sclerosis, a systematic review and meta-analysis.
    J Neurol Sci. 2020;411:116668.
    PubMed     Abstract available


    December 2019
  31. GROMISCH ES, Foley FW
    Can semantic fluency be used as an alternative or additional measure in the abbreviated Minimal Assessment of Cognitive Function in Multiple Sclerosis (aMACFIMS)?
    J Neurol Sci. 2019;410:116640.
    PubMed     Abstract available


  32. DE CARVALHO JENNINGS PEREIRA W, Flauzino T, Alfieri DF, Oliveira SR, et al
    Immune-inflammatory, metabolic and hormonal biomarkers are associated with the clinical forms and disability progression in patients with multiple sclerosis: A follow-up study.
    J Neurol Sci. 2019;410:116630.
    PubMed     Abstract available


  33. FUJII T, Yamasaki R, Miyachi Y, Nagata S, et al
    Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis.
    J Neurol Sci. 2019;409:116619.
    PubMed     Abstract available


  34. CRISTIANO E, Rojas JI, Alonso R, Alvez Pinheiro A, et al
    Consensus recommendations on the management of multiple sclerosis patients in Argentina.
    J Neurol Sci. 2019;409:116609.
    PubMed     Abstract available


    November 2019
  35. ZANETTA C, Robotti M, Nozzolillo A, Sangalli F, et al
    Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature.
    J Neurol Sci. 2019;409:116603.
    PubMed    


    October 2019
  36. UYGUR M, de Freitas PB, Barone DA
    Rate of force development and relaxation scaling factors are highly sensitive to detect upper extremity motor impairments in multiple sclerosis.
    J Neurol Sci. 2019;408:116500.
    PubMed     Abstract available


  37. CEDERBERG KLJ, Jeng B, Sasaki JE, Braley TJ, et al
    Physical activity, sedentary behavior, and restless legs syndrome in persons with multiple sclerosis.
    J Neurol Sci. 2019;407:116531.
    PubMed     Abstract available


    September 2019
  38. SRIWASTAVA S, Yarraguntla K, Zutshi D, Basha MM, et al
    Relevance of cerebrospinal fluid findings in patients with multiple sclerosis and seizures.
    J Neurol Sci. 2019;406:116482.
    PubMed     Abstract available


  39. O'HERLIHY F, John NA, Li V, Porter B, et al
    Screening for urinary tract colonisation prior to corticosteroid administration in acute multiple sclerosis relapses: Validation of an updated algorithm.
    J Neurol Sci. 2019;407:116456.
    PubMed     Abstract available


  40. HNILICOVA P, Kantorova E, Polacek H, Grendar M, et al
    Altered hypothalamic metabolism in early multiple sclerosis - MR spectroscopy study.
    J Neurol Sci. 2019;407:116458.
    PubMed     Abstract available


    August 2019
  41. NOHARA S, Ishii A, Yamamoto F, Yanagiha K, et al
    GDF-15, a mitochondrial disease biomarker, is associated with the severity of multiple sclerosis.
    J Neurol Sci. 2019;405:116429.
    PubMed     Abstract available


  42. SA M, Nunes CC, da Silva AM, Mota P, et al
    JC virus antibodies in Portuguese multiple sclerosis patients: JUSTIFY study results.
    J Neurol Sci. 2019;406:116426.
    PubMed     Abstract available


  43. VANOLI E, Montano N, De Angelis G, Badilini F, et al
    Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod.
    J Neurol Sci. 2019;405:116423.
    PubMed     Abstract available


    July 2019
  44. BATCHELLER L, Baker D
    Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?
    J Neurol Sci. 2019;404:19-28.
    PubMed     Abstract available


    June 2019
  45. MUCCILLI A, Nehme A, Labrie M, Girard M, et al
    Varicella-zoster virus vasculopathy in a multiple sclerosis patient on fingolimod.
    J Neurol Sci. 2019;403:119-121.
    PubMed    


  46. SEDEEQ MS, El-Nahrery EMA, Shalaby N, Hussein M, et al
    Micro-RNA-96 and interleukin-10 are independent biomarkers for multiple sclerosis activity.
    J Neurol Sci. 2019;403:92-96.
    PubMed     Abstract available


  47. MINAGAR A, Alexander JS
    Cervical spinal cord atrophy impact on quality of life in MS: A neuroimaging study.
    J Neurol Sci. 2019;401:101-102.
    PubMed    


  48. MASUDA H, Mori M, Hirano S, Kojima K, et al
    Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis.
    J Neurol Sci. 2019;403:78-84.
    PubMed     Abstract available


    May 2019
  49. DE ROQUEMAUREL A, Galli P, Landais A, Avendano S, et al
    Fingolimod for the treatment of multiple sclerosis in French West Indies, a real-world study in patients from African ancestry.
    J Neurol Sci. 2019;402:180-187.
    PubMed     Abstract available


    April 2019
  50. ZURAWSKI J, Glanz BI, Healy BC, Tauhid S, et al
    The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis.
    J Neurol Sci. 2019;403:38-43.
    PubMed     Abstract available


    March 2019
  51. BOZIKI M, Lagoudaki R, Melo P, Kanidou F, et al
    Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
    J Neurol Sci. 2019;401:43-50.
    PubMed     Abstract available


  52. BEIER M, Hughes AJ, Williams MW, Gromisch ES, et al
    Brief and cost-effective tool for assessing verbal learning in multiple sclerosis: Comparison of the Rey Auditory Verbal Learning Test (RAVLT) to the California Verbal Learning Test - II (CVLT-II).
    J Neurol Sci. 2019;400:104-109.
    PubMed     Abstract available


    February 2019
  53. KAPLAN TB, Bove R, Galetta K, Healy B, et al
    Effect of pregnancy loss on MS disease activity.
    J Neurol Sci. 2019;397:58-60.
    PubMed     Abstract available


  54. BEH SC
    The "eye of the tiger" in a patient with multiple sclerosis.
    J Neurol Sci. 2019;399:1-2.
    PubMed    


    January 2019
  55. FOX E, Vieira MC, Johnson K, Peeples M, et al
    Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3years: a retrospective US claims database analysis.
    J Neurol Sci. 2019;398:163-170.
    PubMed     Abstract available


    December 2018
  56. ZACHARZEWSKA-GONDEK A, Pokryszko-Dragan A, Gondek TM, Koltowska A, et al
    Apparent diffusion coefficient measurements in normal appearing white matter may support the differential diagnosis between multiple sclerosis lesions and other white matter hyperintensities.
    J Neurol Sci. 2018;397:24-30.
    PubMed     Abstract available


    November 2018
  57. PENG A, Qiu X, Zhang L, Zhu X, et al
    Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review.
    J Neurol Sci. 2018;396:202-205.
    PubMed    


  58. FRITZ NE, Kloos AD, Kegelmeyer DA, Kaur P, et al
    Supplementary motor area connectivity and dual-task walking variability in multiple sclerosis.
    J Neurol Sci. 2018;396:159-164.
    PubMed     Abstract available


  59. MEJIA M, Rodriguez-Leyva I, Cortes-Enriquez F, Chi-Ahumada E, et al
    Low levels of alpha-synuclein in peripheral tissues are related to clinical relapse in relapsing-remitting multiple sclerosis: a pilot cross-sectional study.
    J Neurol Sci. 2018;396:87-93.
    PubMed     Abstract available


    October 2018
  60. ZILIOTTO N, Zivadinov R, Jakimovski D, Baroni M, et al
    Plasma levels of soluble NCAM in multiple sclerosis.
    J Neurol Sci. 2018;396:36-41.
    PubMed     Abstract available


    September 2018
  61. HEALY BC, Glanz BI, Zurawski JD, Mazzola M, et al
    Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.
    J Neurol Sci. 2018;394:127-131.
    PubMed     Abstract available


  62. POLACHINI CRN, Spanevello RM, Schetinger MRC, Morsch VM, et al
    Cholinergic and purinergic systems: A key to multiple sclerosis?
    J Neurol Sci. 2018;392:8-21.
    PubMed     Abstract available


    August 2018
  63. JAKIMOVSKI D, Weinstock-Guttman B, Hagemeier J, Vaughn CB, et al
    Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage.
    J Neurol Sci. 2018;393:128-134.
    PubMed     Abstract available


  64. POKRYSZKO-DRAGAN A, Banaszek A, Nowakowska-Kotas M, Jezowska-Jurczyk K, et al
    Diffusion tensor imaging findings in the multiple sclerosis patients and their relationships to various aspects of disability.
    J Neurol Sci. 2018;391:127-133.
    PubMed     Abstract available


    July 2018
  65. CRISTIANO E, Rojas JI, Abad P, Adoni T, et al
    Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America.
    J Neurol Sci. 2018;393:4-13.
    PubMed     Abstract available


  66. VOLLMER B, Honce JM, Sillau S, Corboy JR, et al
    The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis.
    J Neurol Sci. 2018;390:89-93.
    PubMed     Abstract available


  67. ZHANG Y, Wang L, Jia H, Liao M, et al
    Genetic variants regulate NR1H3 expression and contribute to multiple sclerosis risk.
    J Neurol Sci. 2018;390:162-165.
    PubMed     Abstract available


    June 2018
  68. KHALID F, Healy BC, Dupuy SL, Chu R, et al
    Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis.
    J Neurol Sci. 2018;392:94-99.
    PubMed     Abstract available


  69. GROMISCH ES, Portnoy JG, Foley FW
    Response to screening ability of cognitive function by two measures in patients with multiple sclerosis.
    J Neurol Sci. 2018 Jun 14. pii: S0022-510X(18)30259.
    PubMed    


  70. KAWADA T
    Screening ability of cognitive function by two measures in patients with multiple sclerosis.
    J Neurol Sci. 2018 Jun 13. pii: S0022-510X(18)30258.
    PubMed    


    May 2018
  71. KADRNOZKOVA L, Vaneckova M, Sobisek L, Benova B, et al
    Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients.
    J Neurol Sci. 2018;388:87-93.
    PubMed     Abstract available


  72. GROMISCH ES, Portnoy JG, Foley FW
    Comparison of the abbreviated minimal assessment of cognitive function in multiple sclerosis (aMACFIMS) and the brief international cognitive assessment for multiple sclerosis (BICAMS).
    J Neurol Sci. 2018;388:70-75.
    PubMed     Abstract available


  73. ZIVADINOV R, Bergsland N, Hagemeier J, Carl E, et al
    Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures.
    J Neurol Sci. 2018;388:175-181.
    PubMed     Abstract available


  74. KANTOR D, Johnson K, Vieira MC, Signorovitch J, et al
    Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2018;388:168-174.
    PubMed     Abstract available


  75. FABIS-PEDRINI MJ, James I, Seewann A, Yau WY, et al
    Natural history of benign multiple sclerosis: Clinical and HLA correlates in a Western Australian cohort.
    J Neurol Sci. 2018;388:12-18.
    PubMed     Abstract available


  76. MANCA R, Sharrack B, Paling D, Wilkinson ID, et al
    Brain connectivity and cognitive processing speed in multiple sclerosis: A systematic review.
    J Neurol Sci. 2018;388:115-127.
    PubMed     Abstract available


    April 2018
  77. DALGAS U, Langeskov-Christensen M, Skjerbaek A, Jensen E, et al
    Is the impact of fatigue related to walking capacity and perceived ability in persons with multiple sclerosis? A multicenter study.
    J Neurol Sci. 2018;387:179-186.
    PubMed     Abstract available


  78. VYVER MV, Beelen R, De Keyser J, Nagels G, et al
    Plasma citrulline levels are increased in patients with multiple sclerosis.
    J Neurol Sci. 2018;387:174-178.
    PubMed     Abstract available


  79. ZIVADINOV R, Bergsland N, Hagemeier J, Tavazzi E, et al
    Effect of switching from glatiramer acetate 20mg/daily to glatiramer acetate 40mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
    J Neurol Sci. 2018;387:152-156.
    PubMed     Abstract available


  80. AKAISHI T, Takahashi T, Nakashima I
    Oligoclonal bands and periventricular lesions in multiple sclerosis will not increase blood-brain barrier permeability.
    J Neurol Sci. 2018;387:129-133.
    PubMed     Abstract available


  81. GRIST JT, Riemer F, McLean MA, Matys T, et al
    Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: Initial evidence from (23)Na-MRI.
    J Neurol Sci. 2018;387:111-114.
    PubMed     Abstract available


    March 2018
  82. FENU G, Lorefice L, Arru M, Sechi V, et al
    Cognition in multiple sclerosis: Between cognitive reserve and brain volume.
    J Neurol Sci. 2018;386:19-22.
    PubMed     Abstract available


    February 2018
  83. MORROW SA, Rosehart H, Sener A, Welk B, et al
    Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis.
    J Neurol Sci. 2018;385:39-44.
    PubMed     Abstract available


  84. BUNAI T, Terada T, Kono S, Yokokura M, et al
    Neuroinflammation following disease modifying therapy in multiple sclerosis: A pilot positron emission tomography study.
    J Neurol Sci. 2018;385:30-33.
    PubMed     Abstract available


  85. CRISTIANO E, Alonso R, Alvez Pinheiro A, Bacile EA, et al
    Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients.
    J Neurol Sci. 2018;385:217-224.
    PubMed     Abstract available


  86. PODBIELSKA M, O'Keeffe J, Hogan EL
    Autoimmunity in multiple sclerosis: role of sphingolipids, invariant NKT cells and other immune elements in control of inflammation and neurodegeneration.
    J Neurol Sci. 2018;385:198-214.
    PubMed     Abstract available


  87. CRISTIANO E, Alonso R, Alvez Pinheiro A, Bacile EA, et al
    Corrigendum to "Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients" [J. Neurol. Sci. 385C (2018) 217-224].
    J Neurol Sci. 2018 Feb 12. pii: S0022-510X(18)30061.
    PubMed    


    January 2018
  88. BERTSCH-GOUT M, Loeb R, Finch AK, Javed A, et al
    High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status.
    J Neurol Sci. 2018;384:61-66.
    PubMed     Abstract available


    December 2017
  89. DALLA-COSTA G, Radaelli M, Maida S, Sangalli F, et al
    Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice.
    J Neurol Sci. 2017;383:166-168.
    PubMed     Abstract available


  90. LINGENBERG A, Laidet M, Armand S, Herrmann FR, et al
    Gait stability in patients treated by fingolimod: A longitudinal pilot study on 9 patients with multiple sclerosis.
    J Neurol Sci. 2017;383:105-107.
    PubMed    


    November 2017
  91. PEREZ-MARTIN MY, Gonzalez-Platas M, Jimenez-Sosa A, Plata-Bello J, et al
    Can fibrinolytic system components explain cognitive impairment in multiple sclerosis?
    J Neurol Sci. 2017;382:66-72.
    PubMed     Abstract available


  92. PLANCHE V, Moisset X, Morello R, Dumont E, et al
    Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    J Neurol Sci. 2017;382:148-154.
    PubMed     Abstract available


  93. LANGESKOV-CHRISTENSEN D, Feys P, Baert I, Riemenschneider M, et al
    Performed and perceived walking ability in relation to the Expanded Disability Status Scale in persons with multiple sclerosis.
    J Neurol Sci. 2017;382:131-136.
    PubMed     Abstract available


    October 2017
  94. YOUSUF F, Dupuy SL, Tauhid S, Chu R, et al
    A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    J Neurol Sci. 2017 Oct 16. pii: S0022-510X(17)34384.
    PubMed     Abstract available


  95. MILLER P, Soundy A
    The pharmacological and non-pharmacological interventions for the management of fatigue related multiple sclerosis.
    J Neurol Sci. 2017;381:41-54.
    PubMed     Abstract available


  96. KARAMI M, Mehrabi F, Allameh A, Pahlevan Kakhki M, et al
    Klotho gene expression decreases in peripheral blood mononuclear cells (PBMCs) of patients with relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2017;381:305-307.
    PubMed     Abstract available


  97. FERREIRA D, Castro P, Videira G, Filipe JP, et al
    Cerebral autoregulation is preserved in multiple sclerosis patients.
    J Neurol Sci. 2017;381:298-304.
    PubMed     Abstract available


  98. CALVI A, De Riz M, Lecchi E, Pietroboni A, et al
    Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
    J Neurol Sci. 2017;381:296-297.
    PubMed    


  99. OLIVEIRA SR, Simao ANC, Alfieri DF, Flauzino T, et al
    Vitamin D deficiency is associated with disability and disease progression in multiple sclerosis patients independently of oxidative and nitrosative stress.
    J Neurol Sci. 2017;381:213-219.
    PubMed     Abstract available


  100. CORREALE J
    Follow-on products for treatment of multiple sclerosis in Latin America: An update.
    J Neurol Sci. 2017;381:153-159.
    PubMed     Abstract available


  101. BEIER M, Gromisch ES, Hughes AJ, Alschuler KN, et al
    Proposed cut scores for tests of the Brief International Cognitive Assessment of Multiple Sclerosis (BICAMS).
    J Neurol Sci. 2017;381:110-116.
    PubMed     Abstract available


  102. MCGEE JC, Minagar A
    Assessing the cerebral gray matter volume in response to fingolimod therapy in multiple sclerosis: A more analytic view.
    J Neurol Sci. 2017 Oct 13. pii: S0022-510X(17)34383.
    PubMed    


    September 2017
  103. YAMOUT BI, Said M, Hannoun S, Zeineddine M, et al
    Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.
    J Neurol Sci. 2017;380:79-81.
    PubMed     Abstract available


  104. YANG TT, Wang L, Deng XY, Yu G, et al
    Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2017;380:256-261.
    PubMed     Abstract available


  105. GREEKE EE, Chua AS, Healy BC, Rintell DJ, et al
    Depression and fatigue in patients with multiple sclerosis.
    J Neurol Sci. 2017;380:236-241.
    PubMed     Abstract available


  106. IWANOWSKI P, Losy J, Kramer L, Wojcicka M, et al
    CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    J Neurol Sci. 2017;380:22-26.
    PubMed     Abstract available


  107. LAIDET M, Herrmann FR, Armand S, Assal F, et al
    Does fear of falling predict gait variability in multiple sclerosis?
    J Neurol Sci. 2017;380:212-214.
    PubMed     Abstract available


  108. SCARPAZZA C, Prosperini L, Mancinelli CR, De Rossi N, et al
    Corrigendum to "Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?" [J. Neurol. Sci. 378 (2017) 233-237].
    J Neurol Sci. 2017;380:19.
    PubMed    


  109. PICELLI A, Vallies G, Chemello E, Castellazzi P, et al
    Is spasticity always the same? An observational study comparing the features of spastic equinus foot in patients with chronic stroke and multiple sclerosis.
    J Neurol Sci. 2017;380:132-136.
    PubMed     Abstract available


    August 2017
  110. SANTORO M, Mirabella M, De Fino C, Bianco A, et al
    Sativex(R) effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.
    J Neurol Sci. 2017;379:298-303.
    PubMed     Abstract available


  111. GAETANI L, Fanelli F, Riccucci I, Eusebi P, et al
    High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline.
    J Neurol Sci. 2017;379:236-240.
    PubMed     Abstract available


  112. KEUNE PM, Young WR, Paraskevopoulos IT, Hansen S, et al
    Measuring standing balance in multiple sclerosis: Further progress towards an automatic and reliable method in clinical practice.
    J Neurol Sci. 2017;379:157-162.
    PubMed     Abstract available


  113. MORSALJAHAN Z, Rafiei A, Valadan R, Abedini M, et al
    Association between interleukin-32 polymorphism and multiple sclerosis.
    J Neurol Sci. 2017;379:144-150.
    PubMed     Abstract available


    July 2017
  114. FARROKHI M, Masoudifar A, Peykanpour F
    Interleukin 17 and 10 in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2017;378:63.
    PubMed    


  115. ROLF L, Muris AH, Bol Y, Damoiseaux J, et al
    Vitamin D3 supplementation in multiple sclerosis: Symptoms and biomarkers of depression.
    J Neurol Sci. 2017;378:30-35.
    PubMed     Abstract available


  116. SCARPAZZA C, Prosperini L, Mancinelli CR, De Rossi N, et al
    Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
    J Neurol Sci. 2017;378:233-237.
    PubMed     Abstract available


  117. TAWFIK TZ, Gad AH, Mehaney DA, El Nahrery E, et al
    Concerning the article "Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients".
    J Neurol Sci. 2017;378:152.
    PubMed    


    June 2017
  118. AGLIARDI C, Guerini FR, Zanzottera M, Rovaris M, et al
    Indoleamine-2,3-dioxygenase(IDO)2 polymorphisms are not associated with multiple sclerosis in Italians.
    J Neurol Sci. 2017;377:31-34.
    PubMed     Abstract available


  119. CALABRO RS, Russo M, Naro A, De Luca R, et al
    Robotic gait training in multiple sclerosis rehabilitation: Can virtual reality make the difference? Findings from a randomized controlled trial.
    J Neurol Sci. 2017;377:25-30.
    PubMed     Abstract available


  120. TRENTINI A, Castellazzi M, Romani A, Squerzanti M, et al
    Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients.
    J Neurol Sci. 2017;377:133-136.
    PubMed     Abstract available


  121. SMOLDERS J, Rolf L, Damoiseaux J, Hupperts R, et al
    On the ethics of not supplementing low 25-hydroxyvitamin D levels in a controlled study in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2017 Jun 9. pii: S0022-510X(17)30383.
    PubMed    


  122. SHUKLA L, Solanki C, Kulkarni Y, Vadlamani N, et al
    Vitamin D supplementation; effects on depressive symptoms in multiple sclerosis.
    J Neurol Sci. 2017 Jun 9. pii: S0022-510X(17)30384.
    PubMed    


    May 2017
  123. JORGENSEN M, Dalgas U, Wens I, Hvid LG, et al
    Muscle strength and power in persons with multiple sclerosis - A systematic review and meta-analysis.
    J Neurol Sci. 2017;376:225-241.
    PubMed     Abstract available


  124. HEESEN C, Kleiter I, Meuth SG, Kramer J, et al
    Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients.
    J Neurol Sci. 2017;376:181-190.
    PubMed     Abstract available


  125. BSTEH G, Monz E, Zamarian L, Hagspiel S, et al
    Combined evaluation of personality, risk and coping in MS patients: A step towards individualized treatment choice - The PeRiCoMS-Study I.
    J Neurol Sci. 2017;376:71-75.
    PubMed     Abstract available


  126. WEINSTOCK-GUTTMAN B, Nair KV, Glajch JL, Ganguly TC, et al
    Two decades of glatiramer acetate: From initial discovery to the current development of generics.
    J Neurol Sci. 2017;376:255-259.
    PubMed     Abstract available


    April 2017
  127. BOURNE T, Waltz M, Casper TC, Kavak K, et al
    Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population.
    J Neurol Sci. 2017;375:371-375.
    PubMed     Abstract available


  128. LYSANDROPOULOS AP, Mavroudakis N, Pandolfo M, El Hafsi K, et al
    HLA genotype as a marker of multiple sclerosis prognosis: A pilot study.
    J Neurol Sci. 2017;375:348-354.
    PubMed     Abstract available


  129. NOORI-ZADEH A, Mesbah-Namin SA, Saboor-Yaraghi AA
    Epigenetic and gene expression alterations of FOXP3 in the T cells of EAE mouse model of multiple sclerosis.
    J Neurol Sci. 2017;375:203-208.
    PubMed     Abstract available


  130. RUBEGNI A, Battisti C, Tessa A, Cerase A, et al
    SPG2 mimicking multiple sclerosis in a family identified using next generation sequencing.
    J Neurol Sci. 2017;375:198-202.
    PubMed     Abstract available


  131. HARTL C, Obermeier V, Gerdes LA, Brugel M, et al
    Seasonal variations of 25-OH vitamin D serum levels are associated with clinical disease activity in multiple sclerosis patients.
    J Neurol Sci. 2017;375:160-164.
    PubMed     Abstract available


  132. REEN GK, Silber E, Langdon DW
    Multiple sclerosis patients' understanding and preferences for risks and benefits of disease-modifying drugs: A systematic review.
    J Neurol Sci. 2017;375:107-122.
    PubMed     Abstract available


    February 2017
  133. ZHOU Y, Fang L, Peng L, Qiu W, et al
    TLR9 and its signaling pathway in multiple sclerosis.
    J Neurol Sci. 2017;373:95-99.
    PubMed     Abstract available


  134. WUNDES A, Bowen JD, Kraft GH, Maravilla KR, et al
    Brain pathology of a patient 7years after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    J Neurol Sci. 2017;373:339-341.
    PubMed     Abstract available


  135. LANGESKOV-CHRISTENSEN M, Bisson EJ, Finlayson ML, Dalgas U, et al
    Potential pathophysiological pathways that can explain the positive effects of exercise on fatigue in multiple sclerosis: A scoping review.
    J Neurol Sci. 2017;373:307-320.
    PubMed     Abstract available


  136. FERREIRA KP, Oliveira SR, Kallaur AP, Kaimen-Maciel DR, et al
    Disease progression and oxidative stress are associated with higher serum ferritin levels in patients with multiple sclerosis.
    J Neurol Sci. 2017;373:236-241.
    PubMed     Abstract available


  137. KAWADA T
    Poor sleep and fatigue in patients with multiple sclerosis.
    J Neurol Sci. 2017;373:143.
    PubMed    


  138. NOCITI V, Losavio FA, Gnoni V, Losurdo A, et al
    Response to the letter to the Editor for the manuscript "Sleep and Fatigue in Multiple Sclerosis: A questionnaire-based, cross-sectional, cohort study" by Tomoyuki Kawada.
    J Neurol Sci. 2017;373:142.
    PubMed    


  139. ZAHOOR I, Haq E, Asimi R
    Multiple sclerosis in Kashmir: Where we stand.
    J Neurol Sci. 2017;373:129-133.
    PubMed     Abstract available


  140. TOGHI M, Taheri M, Arsang-Jang S, Ohadi M, et al
    SOCS gene family expression profile in the blood of multiple sclerosis patients.
    J Neurol Sci. 2017 Feb 9. pii: S0022-510X(17)30111.
    PubMed     Abstract available


    January 2017
  141. ALGAHTANI H, Marzouk Y, Algahtani R, Salman S, et al
    Autosomal Recessive Cerebellar Ataxia type 1 mimicking multiple sclerosis: A report of two siblings with a novel mutation in SYNE1 gene in a Saudi family.
    J Neurol Sci. 2017;372:97-100.
    PubMed     Abstract available


  142. MOTL RW, Sandroff BM, Pilutti LA, Klaren RE, et al
    Physical activity, sedentary behavior, and aerobic capacity in persons with multiple sclerosis.
    J Neurol Sci. 2017;372:342-346.
    PubMed     Abstract available


  143. BOESCHOTEN RE, Braamse AM, Beekman AT, Cuijpers P, et al
    Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2017;372:331-341.
    PubMed     Abstract available


  144. CAMEROTA F, Celletti C, Di Sipio E, De Fino C, et al
    Focal muscle vibration, an effective rehabilitative approach in severe gait impairment due to multiple sclerosis.
    J Neurol Sci. 2017;372:33-39.
    PubMed     Abstract available


  145. SABATINO JJ JR, Newsome SD
    Stiff person syndrome masquerading as multiple sclerosis.
    J Neurol Sci. 2017;372:297-299.
    PubMed     Abstract available


  146. CRNOSIJA L, Krbot Skoric M, Gabelic T, Adamec I, et al
    Vestibular evoked myogenic potentials and MRI in early multiple sclerosis: Validation of the VEMP score.
    J Neurol Sci. 2017;372:28-32.
    PubMed     Abstract available


  147. KISIC-TEPAVCEVIC D, Pekmezovic T, Trajkovic G, Stojsavljevic N, et al
    Corrigendum to "Sexual dysfunction in multiple sclerosis: A 6-year follow-up study" [J. Neurol. Sci. 358 (2015) 317-323].
    J Neurol Sci. 2017;372:201.
    PubMed    


  148. CHALAH MA, Riachi N, Ahdab R, Mhalla A, et al
    Effects of left DLPFC versus right PPC tDCS on multiple sclerosis fatigue.
    J Neurol Sci. 2017;372:131-137.
    PubMed     Abstract available


  149. TAO C, Simpson S Jr, Taylor BV, van der Mei I, et al
    Association between human herpesvirus & human endogenous retrovirus and MS onset & progression.
    J Neurol Sci. 2017;372:239-249.
    PubMed     Abstract available


  150. BEH SC, Kildebeck E, Narayan R, Desena A, et al
    High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes.
    J Neurol Sci. 2017;372:187-195.
    PubMed     Abstract available


  151. TANIKAWA M, Nakahara J, Hata J, Suzuki S, et al
    q-Space Myelin Map imaging for longitudinal analysis of demyelination and remyelination in multiple sclerosis patients treated with fingolimod: A preliminary study.
    J Neurol Sci. 2017 Jan 5. pii: S0022-510X(17)30010.
    PubMed     Abstract available


  152. KIRA JI
    q-space Myelin Map imaging: A new imaging technique for treatment evaluation in multiple sclerosis.
    J Neurol Sci. 2017 Jan 4. pii: S0022-510X(17)30009.
    PubMed    


    December 2016
  153. KOUDRIAVTSEVA T
    Body mass index and interferon-beta efficacy (and safety) in multiple sclerosis.
    J Neurol Sci. 2016;371:79-80.
    PubMed    


    November 2016
  154. HERNANDEZ ME, Holtzer R, Chaparro G, Jean K, et al
    Brain activation changes during locomotion in middle-aged to older adults with multiple sclerosis.
    J Neurol Sci. 2016;370:277-283.
    PubMed     Abstract available


  155. SQUINTANI G, Donato F, Turri M, Deotto L, et al
    Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    J Neurol Sci. 2016;370:263-268.
    PubMed     Abstract available


  156. O'GORMAN CM, Broadley SA
    Smoking increases the risk of progression in multiple sclerosis: A cohort study in Queensland, Australia.
    J Neurol Sci. 2016;370:219-223.
    PubMed     Abstract available


  157. DE GIGLIO L, Upadhyay N, De Luca F, Prosperini L, et al
    Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis.
    J Neurol Sci. 2016;370:211-213.
    PubMed    


  158. GAINDH D, Kavak KS, Teter B, Vaughn CB, et al
    Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.
    J Neurol Sci. 2016;370:13-17.
    PubMed     Abstract available


  159. GASPERINI C, Hupperts R, Lycke J, Short C, et al
    Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
    J Neurol Sci. 2016;370:123-131.
    PubMed     Abstract available


  160. HUHN K, Lammer R, Zimmermann H, Lammer A, et al
    Retinal imaging and axonal degeneration in later onset multiple sclerosis.
    J Neurol Sci. 2016;370:1-6.
    PubMed     Abstract available


    October 2016
  161. NOCITI V, Losavio FA, Gnoni V, Losurdo A, et al
    Sleep and fatigue in multiple sclerosis: A questionnaire-based, cross-sectional, cohort study.
    J Neurol Sci. 2016 Oct 27. pii: S0022-510X(16)30684.
    PubMed     Abstract available


  162. EFTEKHARIAN MM, Noroozi R, Sayad A, Sarrafzadeh S, et al
    RAR-related orphan receptor A (RORA): A new susceptibility gene for multiple sclerosis.
    J Neurol Sci. 2016;369:259-62.
    PubMed     Abstract available


  163. BERNARDINI LR, Zecca C, Clerici VT, Gobbi C, et al
    Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis.
    J Neurol Sci. 2016;369:139-40.
    PubMed    


  164. YANG F, Estrada EF, Sanchez MC
    Vibration training improves disability status in multiple sclerosis: A pretest-posttest pilot study.
    J Neurol Sci. 2016;369:96-101.
    PubMed     Abstract available


  165. MANDEL JJ, Goethe EA, Patel AJ, Heck K, et al
    Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis.
    J Neurol Sci. 2016;369:51-2.
    PubMed    


  166. TAWFIK TZ, Gad AH, Mehaney DA, El Nahrery E, et al
    Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
    J Neurol Sci. 2016;369:36-8.
    PubMed     Abstract available


    September 2016
  167. BRAMBILLA L, Rossi Sebastiano D, Aquino D, Torri Clerici V, et al
    Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
    J Neurol Sci. 2016;368:402-7.
    PubMed     Abstract available


  168. MESSMER UCCELLI M, Traversa S, Ponzio M
    A survey study comparing young adults with MS and healthy controls on self-esteem, self-efficacy, mood and quality of life.
    J Neurol Sci. 2016;368:369-73.
    PubMed     Abstract available


  169. SACCA F, Pane C, Carotenuto A, Massarelli M, et al
    The use of medical-grade cannabis in patients non-responders to Nabiximols.
    J Neurol Sci. 2016;368:349-51.
    PubMed    


    June 2016
  170. KUUSISTO H, Vahvelainen T, Hamalainen P, Luukkaala T, et al
    Asymptomatic subjects differ less from their twin siblings with MS than from healthy controls in cognitive functioning. A Finnish Twin Cohort study.
    J Neurol Sci. 2016;365:50-3.
    PubMed     Abstract available


    April 2016
  171. TREMLETT H, Fadrosh DW, Faruqi AA, Hart J, et al
    Gut microbiota composition and relapse risk in pediatric MS: A pilot study.
    J Neurol Sci. 2016;363:153-7.
    PubMed     Abstract available


    March 2016
  172. HUDA S, Cavey A, Izat A, Mattison P, et al
    Nurse led telephone assessment of expanded disability status scale assessment in MS patients at high levels of disability.
    J Neurol Sci. 2016;362:66-8.
    PubMed     Abstract available


    January 2016
  173. MOORE P, Methley A, Pollard C, Mutch K, et al
    Cognitive and psychiatric comorbidities in neuromyelitis optica.
    J Neurol Sci. 2016;360:4-9.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: